Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized vs Fixed Dose ATG for GVHD Prophylaxis in Haplo-PBSCT
NCT05166967Phase 3Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2022
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of antithymocyte globulin in graft-versus-host disease (GVHD), sponsored by Chinese PLA General Hospital. Started Jan 2022; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05166967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166967.